This study suggests that opioid administration will increase the risk of mortality associated with sepsis in ICU patients, and neutralization of IL-17A might be a novel strategy to control excess inflammation and improve survival in septic ICU patients who are receiving opioids for pain management (Supplementary Fig. 9). This evidence concerns the gene IL17A and Sepsis.